<DOC>
	<DOCNO>NCT00479921</DOCNO>
	<brief_summary>Influenza ( flu ) viruses change continuously , therefore also part virus use influenza vaccine vary year year . In Europe , manufacturers/marketing holder vaccine require involved ongoing clinical trial present result competent authority year . The current study phase IIIa clinical trial commercially available vaccine ( Influvac® ) supply pre fill syrinx . It part ongoing clinical trial program Influvac® do ass immunogenicity safety tolerability next season 's trivalent influenza subunit vaccine two group healthy subject : subject age &gt; = 18 &lt; = 60 year subject &gt; = 61 year age ( elderly ) .</brief_summary>
	<brief_title>Annual Study Investigate Influenza Vaccine Due New Virus Strains 2007/2008 Influenza Season Europe</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Signed date informed consent . Healthy age &gt; = 18 &lt; = 60 year &gt; = 61 year age . Mental health good enough understand study inform consent form fill questionnaire . Known allergic egg , chicken protein , gentamicin constituent vaccine . Having fever and/or present acute infectious episode upper and/or lower respiratory airway . Having experience serious systemic and/or local reaction previous influenza vaccination . Having autoimmune disorder ( e.g . RA , SLE , autoimmune thyroid disorder ) disorder affect immune system , take immunosuppressive medication ( systemic corticosteroid ) include four week precede start study ( date inform consent ) , disease terminal stage . Having receive vaccination influenza within previous six month Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>CHMP criterion</keyword>
</DOC>